Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Exclusion Criteria

• •Is currently participating and receiving trial therapy or has participated in a trial of an investigational agent and received trial therapy or used an investigational device within 3 weeks of the first dose of trial treatment.
• •Hypersensitivity to cabiralizumab, nivolumab, or gemcitabine or any of its excipients.
• •Previous malignancies (except non-melanoma skin cancers, and in situ bladder, gastric, colorectal, endometrial, cervical/dysplasia, melanoma, or breast cancers) unless complete remission was achieved at least 2 years prior to study entry and no additional therapy is required during the study period.
• •Evidence of central nervous system (CNS) metastasis
• •Participants with active, known, or suspected autoimmune disease.
• •Current or history of clinically significant muscle disorders (e.g., myositis), recent unresolved muscle injury, or any condition known to elevate serum CK levels.
• •Uncontrolled or significant cardiovascular disease
• •Prior organ allograft or allogeneic bone marrow transplantation.
• •Any uncontrolled inflammatory GI disease including Crohn's Disease and ulcerative colitis.
• •Evidence of coagulopathy or bleeding diathesis.
• •Has received prior therapy with a CSF-1R pathway inhibitors, anti-PD-1, anti-PD-L1, anti PD-L2, anti-CTLA-4.